RetroVirox

ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs (video) for respiratory disease complexes and innovative vaccines (video) for viral infections in swine leading the pipeline. We are developing novel and innovative vaccines using a rather unique technology platform. We develop fast acting antiviral drugs that are crucial to the effective control and treatment of respiratory diseases of cattle and swine and that will also reduce secondary infections and the associated use of antibiotics. This technology enables the mass production of inexpensive modified live virus (MLV) vaccines that can be tailor-made to maximize efficacy and minimize safety concerns, while removing the cold chain requirement.

Retrovirology is an open access, online journal that publishes stringently peer-reviewed, high-impact articles on host-pathogen interactions, fundamental mechanisms of replication, immune defences, animal models, and clinical science relating to retroviruses. Retrovirology aims to cover comprehensively all aspects of human and animal retrovirus research. All articles published by Retrovirology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. All articles published in Retrovirology are included in:. Retrovirology operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. All manuscripts submitted to Retrovirology should adhere to BioMed Central's editorial policies. Articles in Retrovirology should be cited in the same way as articles in a traditional journal. Retrovirology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.

ViraTherapeutics is a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies. ViraTherapeutics specializes in the development of highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. ViraTherapeutics currently performs preclinical safety and efficacy studies for our modified Vesicular Stomatitis Virus (VSV-GP) and aims to conduct first clinical trials in cancer patients in the near future. We are committed to developing new treatments for people living with cancer and improving their quality of life. Take your chance and check our recent job offers.

NeoVirTech’s mission is to provide researcher state of the art virology assays using innovative, image based readout. At NeoVirTech we have developed an ever-expanding catalogue of autofluorescent viruses and viral vectors for the direct imaging of antiviral drug candidates effect or disinfection procedure in the field of human health, animal health and biodefense. Our goal is to speed up discovery process of any solution having an impact in the infectious disease field. The genesis of NeoVirTech is based on the discovery of the ANCHOR™ technology that allows real-time visualization in living cells of any kind of cellular or foreign DNA. NeoVirTech has developed a breakthrough technology to directly visualize and quantify in real time virus/viral vector infection and replication in living cells. The company exploits and provides access to its proprietary ANCHOR™ technology to both academic and industrial customers and has the ability to convert any kind of DNA into an autofluorescent particle. Among our CRO activities, we have also developed proprietary product displaying broad spectrum antiviral activities that we are positioning on emerging market. Franck has nearly 20 years of experience in the field of cellular biology and microscopy and 10 years of experience in virology.

Viravaxx AG is a privately held company based in Vienna, Austria. One flagship project is a vaccine against Hepatitis B. The newly developed vaccine is a step towards the therapeutic as well as prophylactic use of vaccination against chronic hepatitis B.

Virongy provides scientists and clinicians with innovative technologies for studying viruses and viral vectors. Our services meet the highest academic and industry standards, accelerating scientific discoveries, clinical diagnostics, and disease treatment.